ARUP Laboratories v. Pacific Medical Laboratory

CourtDistrict Court, D. Utah
DecidedJanuary 12, 2022
Docket2:20-cv-00186
StatusUnknown

This text of ARUP Laboratories v. Pacific Medical Laboratory (ARUP Laboratories v. Pacific Medical Laboratory) is published on Counsel Stack Legal Research, covering District Court, D. Utah primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ARUP Laboratories v. Pacific Medical Laboratory, (D. Utah 2022).

Opinion

UNITED STATES DISTRICT COURT FOR THE DISTRICT OF UTAH CENTRAL DIVISION

ARUP LABORATORIES, INC., MEMORANDUM DECISION AND ORDER GRANTING IN PART AND Plaintiff, DENYING IN PART ARUP’S MOTION FOR SANCTIONS v. (DOC. NO. 55)

PACIFIC MEDICAL LABORATORY, Case No. 2:20-cv-00186 INC., Judge David Barlow Defendant. Magistrate Judge Daphne A. Oberg

Before the court is Plaintiff ARUP Laboratories, Inc.’s (“ARUP”) Motion for Sanctions, (“Mot.,” Doc. No. 55). ARUP seeks sanctions against Defendant Pacific Medical Laboratory, Inc. (“PML”) in connection with (1) the failure by PML and its officers, Dr. Reza Zarghami and Dr. Jalal Zarghami, to appear at their depositions on August 3 and 5, 2021; (2) PML’s failure to properly prepare its Rule 30(b)(6) designee, and other obstreperous conduct during PML’s 30(b)(6) deposition; and (3) a dispute regarding ARUP’s request for PML’s counsel to remain visible and unmuted during virtual depositions. (Id. at 1–2.) ARUP also seeks its attorney fees and costs incurred in bringing the motion for sanctions. (Id. at 2.) The court heard argument on the motion on January 4, 2022. (See Doc. No. 63.) For the reasons explained below, the court grants the motion in part and denies it in part. BACKGROUND In this action, ARUP raises claims against PML for breach of contract, claim on account/services provided, and unjust enrichment. (Am. Compl. ¶¶ 6–29, Doc. No. 38.) ARUP’s primary allegation is that PML failed to pay four invoices reflecting laboratory services ARUP provided. (Id. at ¶¶ 7–15.) PML asserts counterclaims against ARUP for breach of contract, breach of the implied covenant of good faith and fair dealing, unjust enrichment, and declaratory relief. (Am. Countercl. ¶¶ 41–64, Doc. No. 30.) PML alleges ARUP charged higher rates than those allowed under the parties’ contract and failed to use the appropriate billing

codes, thereby interfering with PML’s ability to obtain reimbursement from Medi-Cal. (Id. ¶¶ 16–18, 20–24). Under the most recent scheduling order, the close of fact discovery was August 15, 2021. (Third Am. Scheduling Order, Doc. No. 46.) As set forth in ARUP’s motion and attached exhibits, between March and August 2021, ARUP made numerous attempts to schedule the depositions of PML, PML president Dr. Reza Zarghami (“Dr. Reza”), and PML chief operating officer Dr. Jalal Zarghami (“Dr. Jalal”). (Mot. 6–7, Doc. No. 55; see generally Exs. A & B to Mot., Emails Between ARUP’s Counsel and PML’s Counsel, Doc. Nos. 55-1 & 55-2.) On June 21, ARUP’s counsel proposed July 12–15 or August 3–5 for the depositions. (Mot. 7, Doc. No. 55; Ex. B to Mot., Doc. No. 55-2 at 3.) ARUP’s counsel sent follow-up emails on June 25 and July 6, but PML’s counsel did not

confirm whether those dates were available. (Mot. 7, Doc. No. 55; Ex. B to Mot., Doc. No. 55-2 at 2–3.) On July 7, with the August 15 fact discovery deadline approaching, ARUP set the depositions for August 3 and 5 and sent notices. (Mot. 7, Doc. No. 55; Ex. B to Mot., Doc. No. 55-2 at 2, 5.) On August 2, at approximately 5:00 p.m., PML’s counsel called ARUP’s counsel and advised that neither Dr. Reza nor Dr. Jalal were planning to attend their depositions on August 3 or 5—in either their personal or 30(b)(6) capacities. (Mot. 7–8, Doc. No. 55; Ex. D to Mot., Dep. of Reza Zarghami, Aug. 3, 2021 (“August 3 Dep.”), Doc. No. 55-4.) Later that evening, PML’s counsel proposed August 16, 17, or 18—dates after the close of fact discovery—as alternatives. (Ex. C to Mot., Email from PML’s Counsel to ARUP’s Counsel (Aug. 2, 2021 7:01 PM), Doc. No. 55-3.) PML’s counsel also notified ARUP’s counsel that Dr. Reza would be PML’s 30(b)(6) designee for all topics. (Ex. C to Mot., Email from PML’s Counsel to ARUP’s Counsel (Aug. 2, 2021 7:16 PM), Doc. No. 55-3.)

ARUP’s counsel and PML’s counsel appeared virtually, via Zoom, for the scheduled depositions on August 3 and 5 and made a record of the deponents’ failure to appear. (August 3 Dep., Doc. No. 55-4; Ex. E to Mot., Dep. of Jalal Zarghami, Aug. 5, 2021, Doc. No. 55-5.) PML’s counsel explained there had been a “miscommunication” between him, PML’s local California counsel,1 and their client regarding whether the depositions were going forward. (August 3 Dep. 8:1–10, Doc. No. 55-4.) Dr. Reza later testified he did not appear on August 3 because of a “miscommunication,” and said he had not been informed the deposition was scheduled for August 3. (Ex. F to Mot., Dep. of Reza Zarghami, Aug. 17, 2021 (“Reza Dep.”) 11:3–16, Doc. No. 55-6.) Similarly, Dr. Jalal testified he did not know about the deposition scheduled for August 5. (Ex. G to Mot., Dep. of Jalal Zarghami, Aug. 19, 2021 (“Jalal Dep.”)

17:1–10, Doc. No. 55-7.) The parties later proceeded with the depositions on August 17 and 19. Dr. Reza was deposed on August 17, both as PML’s sole 30(b)(6) designee and in his personal capacity. (Reza Dep., Doc. No. 55-6.) Dr. Reza initially testified he prepared for the deposition by speaking to his attorneys for less than an hour and did not review any documents. (Id. at 10:18–11:2.) He later testified he reviewed the 30(b)(6) notice for the first time the day before the deposition and reviewed some other documents the day before and the morning of the deposition. (Id. at 217:24–218:12, 226:2–11). As described in greater detail below, at numerous times throughout

1 PML’s California counsel has not entered an appearance in this case. the deposition, Dr. Reza indicated he did not know the answers to ARUP’s questions on 30(b)(6) topics and suggested Dr. Jalal would be better suited to answer them. Partway through the deposition, PML’s counsel attempted to designate Dr. Jalal as the 30(b)(6) designee for any topics on which Dr. Reza was unable to testify. (Id. at 84:6–12.) ARUP’s counsel rejected this

idea, stating it was inappropriate to designate a new witness after Dr. Reza had given his responses. (Id. at 84:13–18.) Dr. Jalal was then deposed solely in his personal capacity on August 19. (Jalal Dep., Doc. No. 55-7.) During the August 17 deposition, PML’s California counsel was in the same room as Dr. Reza. ARUP’s counsel asked them to keep their microphones unmuted while in the same room and asked that counsel’s face remain visible. (See Reza Dep. 82:16–88:21, 113:5–115:14, Doc. No. 55-6.) She noted she had seen their lips moving while their microphones were muted, including while questions were being asked. (See id.) PML’s California counsel declined, citing issues with microphone feedback and stating he was not required to remain visible. (See id.) When PML later declined to agree to have its California counsel remain visible and unmuted

during Dr. Jalal’s deposition, ARUP requested a hearing to resolve the issue. (See Ex. J to Mot., Emails Between ARUP’s Counsel and PML’s Counsel (Aug. 18, 2021), Doc. No. 55-10 at 2.) The court held a telephone conference on August 19, before Dr. Jalal’s deposition began, and ordered that during virtual depositions, any person in the same room as the deponent be visible on camera with his/her/their microphone unmuted. (See Minute Entry (Aug. 19, 2021), Doc. No. 51.) ARUP moved for sanctions related to these depositions, (Mot., Doc. No. 55), and PML filed an opposition, (Opp’n,2 Doc. No. 58). After the opposition was filed but before the hearing on the motion, PML obtained new counsel to represent it in this case. (See Notice of Substitution of Counsel, Doc. No. 61.)

LEGAL STANDARDS Rule 37 of the Federal Rules of Civil Procedure permits a court to order sanctions if a party’s officer or 30(b)(6) designee “fails, after being served with proper notice, to appear for that person’s deposition.” Fed. R. Civ. P.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

ECCLESIASTES 9: 10-11-12, INC. v. LMC Holding Co.
497 F.3d 1135 (Tenth Circuit, 2012)
Starlight International Inc. v. Herlihy
186 F.R.D. 626 (D. Kansas, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
ARUP Laboratories v. Pacific Medical Laboratory, Counsel Stack Legal Research, https://law.counselstack.com/opinion/arup-laboratories-v-pacific-medical-laboratory-utd-2022.